E Sander ConnollyJr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
E Sander ConnollyJr has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
David J. Pinsky
Columbia University
12 shared publicationsWilliam J. Mack
Columbia University
12 shared publicationsJ Mocco
Department of Neurological Surgery, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
9 shared publications- Judy Huang
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States
8 shared publications Robert A. Solomon
Columbia University Medical Center
7 shared publicationsAndrew F. Ducruet
Department of Neurological Surgery, Columbia University, New York, NY, USA
6 shared publications
Latest Publications
- Open Access
- 30 July 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1723
Therapeutic Modulation of the Complement Cascade in Stroke
Stroke is a leading cause of death and disability worldwide and an increasing number of ischemic stroke patients are undergoing pharmacological and mechanical reperfusion. Both human and experimental models of reperfused ischemic stroke have implicated the complement cascade in secondary tissue injury. Most data point to the lectin and alternative pathways as key to activation, and C3a and C5a binding of their receptors as critical effectors of injury. During periods of thrombolysis use to treat stroke, acute experimental complement cascade blockade has been found to rescue tissue and improves functional outcome. Blockade of the complement cascade during the period of tissue reorganization, repair, and recovery is by contrast not helpful and in fact is likely to be deleterious with emerging data suggesting downstream upregulation of the cascade might even facilitate recovery. Successful clinical translation will require the right clinical setting and pharmacologic strategies that are capable of targeting the key effectors early while not inhibiting delayed repair. Early reports in a variety of disease states suggest that such pharmacologic strategies appear to have a favorable risk profile and offer substantial hope for patients.
- 30 July 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1723
Open AccessTherapeutic Modulation of the Complement Cascade in Stroke
Stroke is a leading cause of death and disability worldwide and an increasing number of ischemic stroke patients are undergoing pharmacological and mechanical reperfusion. Both human and experimental models of reperfused ischemic stroke have implicated the complement cascade in secondary tissue injury. Most data point to the lectin and alternative pathways as key to activation, and C3a and C5a binding of their receptors as critical effectors of injury. During periods of thrombolysis use to treat stroke, acute experimental complement cascade blockade has been found to rescue tissue and improves functional outcome. Blockade of the complement cascade during the period of tissue reorganization, repair, and recovery is by contrast not helpful and in fact is likely to be deleterious with emerging data suggesting downstream upregulation of the cascade might even facilitate recovery. Successful clinical translation will require the right clinical setting and pharmacologic strategies that are capable of targeting the key effectors early while not inhibiting delayed repair. Early reports in a variety of disease states suggest that such pharmacologic strategies appear to have a favorable risk profile and offer substantial hope for patients.
- 30 September 2017
- Published by Springer Nature
- p. 119-136
Aneurysms of the Anterior Circulation
- 10 April 2017
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 18 (6) , 573-580
Current and future perspectives on the treatment of cerebral ischemia
Introduction: After heart disease and combined forms of cancer, stroke is the leading cause of death in the United States. Currently, tissue-plasminogen activator (tPA) thrombolysis is the only thrombolytic therapy that has been shown to improve patient outcome. Presently, the only antithrombotic drug treatment that has proven effective at improving acute ischemic stroke patient outcome is aspirin administration. Despite these studies, no clinical trials have yet demonstrated a reliably effective pharmacological treatment. Areas covered: We conducted a search of recent drug studies for ischemic stroke on clinicaltrials.gov in addition to a literature search for acute ischemic stroke therapy using PubMed. This review details our findings of recent advancements in the pharmacological treatment of acute ischemic stroke. Expert commentary: We concluded that recent attempts to establish new pharmacological treatment protocols for acute ischemic stroke have had limited success, but many Phase III and Phase IV clinical trials demonstrate promise. Moreover, several studies have demonstrated the efficacy of dual-antiplatelet therapies at reducing risk of secondary stroke. Studies for novel therapeutic targets for neuroprotection have been largely unsuccessful. Some trials had positive results; however, there is much room for improvement and other studies show promise in their preliminary stages.
- 10 April 2017
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 18 (6) , 573-580
Current and future perspectives on the treatment of cerebral ischemia
Introduction: After heart disease and combined forms of cancer, stroke is the leading cause of death in the United States. Currently, tissue-plasminogen activator (tPA) thrombolysis is the only thrombolytic therapy that has been shown to improve patient outcome. Presently, the only antithrombotic drug treatment that has proven effective at improving acute ischemic stroke patient outcome is aspirin administration. Despite these studies, no clinical trials have yet demonstrated a reliably effective pharmacological treatment. Areas covered: We conducted a search of recent drug studies for ischemic stroke on clinicaltrials.gov in addition to a literature search for acute ischemic stroke therapy using PubMed. This review details our findings of recent advancements in the pharmacological treatment of acute ischemic stroke. Expert commentary: We concluded that recent attempts to establish new pharmacological treatment protocols for acute ischemic stroke have had limited success, but many Phase III and Phase IV clinical trials demonstrate promise. Moreover, several studies have demonstrated the efficacy of dual-antiplatelet therapies at reducing risk of secondary stroke. Studies for novel therapeutic targets for neuroprotection have been largely unsuccessful. Some trials had positive results; however, there is much room for improvement and other studies show promise in their preliminary stages.
- 1 April 2017
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 28 (2)
Subdural Hematomas
- 1 April 2017
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 28 (2)
Subdural Hematomas
- 1 March 2017
- Published by Oxford University Press (OUP)
Vascular Biology of Cerebral Ischemia
Carotid stenosis may be treated by carotid endarterectomy (CEA) or carotid artery stenting (CAS). Moderate asymptomatic carotid stenosis (50%-70%) is associated with a low risk of ischemic stroke and does not warrant treatment. The severe stenosis (>70%) population sees a marginal benefit in seen with CEA. In the Asymptomatic Carotid Atherosclerosis Study, authors concluded that for patients with less than 60% stenosis, a 5.9% absolute risk reduction was obtained over 5 years with CEA compared with maximum medical management (11 vs. 5.1%).
- 1 March 2017
- Published by Oxford University Press (OUP)
Vascular Biology of Cerebral Ischemia
Carotid stenosis may be treated by carotid endarterectomy (CEA) or carotid artery stenting (CAS). Moderate asymptomatic carotid stenosis (50%-70%) is associated with a low risk of ischemic stroke and does not warrant treatment. The severe stenosis (>70%) population sees a marginal benefit in seen with CEA. In the Asymptomatic Carotid Atherosclerosis Study, authors concluded that for patients with less than 60% stenosis, a 5.9% absolute risk reduction was obtained over 5 years with CEA compared with maximum medical management (11 vs. 5.1%).
- 1 October 2016
- Published by Elsevier in World Neurosurgery
- Vol. 94, 453-457
Analysis of Hemorrhage Volumes After Angiogram-Negative Subarachnoid Hemorrhage
- 1 October 2016
- Published by Elsevier in World Neurosurgery
- Vol. 94, 453-457
Analysis of Hemorrhage Volumes After Angiogram-Negative Subarachnoid Hemorrhage
- 1 October 2014
- Published by Oxford University Press (OUP)
- p. 86-93
Subdural and Epidural Hemorrhage
- Top Cited PapersOpen Access
- 22 August 2014
- Published by Springer Nature in Archives of Public Health
- Vol. 72 (1) , 28
Smart wearable body sensors for patient self-assessment and monitoring
Innovations in mobile and electronic healthcare are revolutionizing the involvement of both doctors and patients in the modern healthcare system by extending the capabilities of physiological monitoring devices. Despite significant progress within the monitoring device industry, the widespread integration of this technology into medical practice remains limited. The purpose of this review is to summarize the developments and clinical utility of smart wearable body sensors.
- 22 August 2014
- Published by Springer Nature in Archives of Public Health
- Vol. 72 (1) , 28
Top Cited PapersOpen AccessSmart wearable body sensors for patient self-assessment and monitoring
Innovations in mobile and electronic healthcare are revolutionizing the involvement of both doctors and patients in the modern healthcare system by extending the capabilities of physiological monitoring devices. Despite significant progress within the monitoring device industry, the widespread integration of this technology into medical practice remains limited. The purpose of this review is to summarize the developments and clinical utility of smart wearable body sensors.
- 22 October 2013
- Published by Springer Nature
- p. 67-85
The Complement Cascade in Acute Brain Injury
- Open Access
- 12 April 2013
- Published by MDPI AG in Brain Sciences
- Vol. 3 (2) , 521-539
Endovascular Thrombectomy Following Acute Ischemic Stroke: A Single-Center Case Series and Critical Review of the Literature
Acute ischemic stroke (AIS) due to thrombo-embolic occlusion in the cerebral vasculature is a major cause of morbidity and mortality in the United States and throughout the world. Although the prognosis is poor for many patients with AIS, a variety of strategies and devices are now available for achieving recanalization in patients with this disease. Here, we review the treatment options for cerebrovascular thromboembolic occlusion with a focus on the evolution of strategies and devices that are utilized for achieving endovascular clot extraction. In order to demonstrate the progression of this treatment strategy over the past decade, we will also present a single-center case series of AIS patients treated with endovascular thrombectomy.
- 12 April 2013
- Published by MDPI AG in Brain Sciences
- Vol. 3 (2) , 521-539
Open AccessEndovascular Thrombectomy Following Acute Ischemic Stroke: A Single-Center Case Series and Critical Review of the Literature
Acute ischemic stroke (AIS) due to thrombo-embolic occlusion in the cerebral vasculature is a major cause of morbidity and mortality in the United States and throughout the world. Although the prognosis is poor for many patients with AIS, a variety of strategies and devices are now available for achieving recanalization in patients with this disease. Here, we review the treatment options for cerebrovascular thromboembolic occlusion with a focus on the evolution of strategies and devices that are utilized for achieving endovascular clot extraction. In order to demonstrate the progression of this treatment strategy over the past decade, we will also present a single-center case series of AIS patients treated with endovascular thrombectomy.